In the changed post COVID-19 business landscape, the global market for Sarcoma Drugs estimated at US$966. 8 Million in the year 2020, is projected to reach a revised size of US$1. 7 Billion by 2027, growing at aCAGR of 8% over the period 2020-2027.
New York, Dec. 26, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Sarcoma Drugs Industry" - https://www.reportlinker.com/p06032828/?utm_source=GNW
Targeted Therapy, one of the segments analyzed in the report, is projected to record 7.8% CAGR and reach US$1.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Chemotherapy segment is readjusted to a revised 8.9% CAGR for the next 7-year period.
The U.S. Market is Estimated at $282.9 Million, While China is Forecast to Grow at 7.5% CAGR
The Sarcoma Drugs market in the U.S. is estimated at US$282.9 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$289.8 Million by the year 2027 trailing a CAGR of 7.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.4% and 6.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 6.5% CAGR.
Select Competitors (Total 42 Featured) -
Amgen
Bayer AG
Eisai Co., Ltd.
Eli Lilly
Johnson and Johnson
Novartis
Pfizer Inc.
Read the full report: https://www.reportlinker.com/p06032828/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Sarcoma Drugs - Global Key Competitors Percentage Market Share
in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Sarcoma Drugs by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR
Table 2: World Historic Review for Sarcoma Drugs by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR
Table 3: World 15-Year Perspective for Sarcoma Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2012, 2021 & 2027
Table 4: World Recent Past, Current & Future Analysis for
Targeted Therapy by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR
Table 5: World Historic Review for Targeted Therapy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR
Table 6: World 15-Year Perspective for Targeted Therapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027
Table 7: World Recent Past, Current & Future Analysis for
Chemotherapy by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR
Table 8: World Historic Review for Chemotherapy by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR
Table 9: World 15-Year Perspective for Chemotherapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027
Table 10: World Sarcoma Drugs Market Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2027
III. MARKET ANALYSIS
UNITED STATES
Sarcoma Drugs Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in the United States for 2022 (E)
Table 11: USA Recent Past, Current & Future Analysis for
Sarcoma Drugs by Treatment Type - Targeted Therapy and
Chemotherapy - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 12: USA Historic Review for Sarcoma Drugs by Treatment
Type - Targeted Therapy and Chemotherapy Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR
Table 13: USA 15-Year Perspective for Sarcoma Drugs by
Treatment Type - Percentage Breakdown of Value Sales for
Targeted Therapy and Chemotherapy for the Years 2012, 2021 &
2027
CANADA
Table 14: Canada Recent Past, Current & Future Analysis for
Sarcoma Drugs by Treatment Type - Targeted Therapy and
Chemotherapy - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 15: Canada Historic Review for Sarcoma Drugs by Treatment
Type - Targeted Therapy and Chemotherapy Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR
Table 16: Canada 15-Year Perspective for Sarcoma Drugs by
Treatment Type - Percentage Breakdown of Value Sales for
Targeted Therapy and Chemotherapy for the Years 2012, 2021 &
2027
JAPAN
Sarcoma Drugs Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Japan for 2022 (E)
Table 17: Japan Recent Past, Current & Future Analysis for
Sarcoma Drugs by Treatment Type - Targeted Therapy and
Chemotherapy - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 18: Japan Historic Review for Sarcoma Drugs by Treatment
Type - Targeted Therapy and Chemotherapy Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR
Table 19: Japan 15-Year Perspective for Sarcoma Drugs by
Treatment Type - Percentage Breakdown of Value Sales for
Targeted Therapy and Chemotherapy for the Years 2012, 2021 &
2027
CHINA
Sarcoma Drugs Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in China for 2022 (E)
Table 20: China Recent Past, Current & Future Analysis for
Sarcoma Drugs by Treatment Type - Targeted Therapy and
Chemotherapy - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 21: China Historic Review for Sarcoma Drugs by Treatment
Type - Targeted Therapy and Chemotherapy Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR
Table 22: China 15-Year Perspective for Sarcoma Drugs by
Treatment Type - Percentage Breakdown of Value Sales for
Targeted Therapy and Chemotherapy for the Years 2012, 2021 &
2027
EUROPE
Sarcoma Drugs Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Europe for 2022 (E)
Table 23: Europe Recent Past, Current & Future Analysis for
Sarcoma Drugs by Geographic Region - France, Germany, Italy, UK
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Table 24: Europe Historic Review for Sarcoma Drugs by
Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR
Table 25: Europe 15-Year Perspective for Sarcoma Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK and Rest of Europe Markets for Years
2012, 2021 & 2027
Table 26: Europe Recent Past, Current & Future Analysis for
Sarcoma Drugs by Treatment Type - Targeted Therapy and
Chemotherapy - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 27: Europe Historic Review for Sarcoma Drugs by Treatment
Type - Targeted Therapy and Chemotherapy Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR
Table 28: Europe 15-Year Perspective for Sarcoma Drugs by
Treatment Type - Percentage Breakdown of Value Sales for
Targeted Therapy and Chemotherapy for the Years 2012, 2021 &
2027
FRANCE
Sarcoma Drugs Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in France for 2022 (E)
Table 29: France Recent Past, Current & Future Analysis for
Sarcoma Drugs by Treatment Type - Targeted Therapy and
Chemotherapy - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 30: France Historic Review for Sarcoma Drugs by Treatment
Type - Targeted Therapy and Chemotherapy Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR
Table 31: France 15-Year Perspective for Sarcoma Drugs by
Treatment Type - Percentage Breakdown of Value Sales for
Targeted Therapy and Chemotherapy for the Years 2012, 2021 &
2027
GERMANY
Sarcoma Drugs Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Germany for 2022 (E)
Table 32: Germany Recent Past, Current & Future Analysis for
Sarcoma Drugs by Treatment Type - Targeted Therapy and
Chemotherapy - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 33: Germany Historic Review for Sarcoma Drugs by
Treatment Type - Targeted Therapy and Chemotherapy Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 34: Germany 15-Year Perspective for Sarcoma Drugs by
Treatment Type - Percentage Breakdown of Value Sales for
Targeted Therapy and Chemotherapy for the Years 2012, 2021 &
2027
ITALY
Table 35: Italy Recent Past, Current & Future Analysis for
Sarcoma Drugs by Treatment Type - Targeted Therapy and
Chemotherapy - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 36: Italy Historic Review for Sarcoma Drugs by Treatment
Type - Targeted Therapy and Chemotherapy Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR
Table 37: Italy 15-Year Perspective for Sarcoma Drugs by
Treatment Type - Percentage Breakdown of Value Sales for
Targeted Therapy and Chemotherapy for the Years 2012, 2021 &
2027
UNITED KINGDOM
Sarcoma Drugs Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in the United Kingdom for 2022 (E)
Table 38: UK Recent Past, Current & Future Analysis for Sarcoma
Drugs by Treatment Type - Targeted Therapy and Chemotherapy -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 39: UK Historic Review for Sarcoma Drugs by Treatment
Type - Targeted Therapy and Chemotherapy Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR
Table 40: UK 15-Year Perspective for Sarcoma Drugs by Treatment
Type - Percentage Breakdown of Value Sales for Targeted Therapy
and Chemotherapy for the Years 2012, 2021 & 2027
REST OF EUROPE
Table 41: Rest of Europe Recent Past, Current & Future Analysis
for Sarcoma Drugs by Treatment Type - Targeted Therapy and
Chemotherapy - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 42: Rest of Europe Historic Review for Sarcoma Drugs by
Treatment Type - Targeted Therapy and Chemotherapy Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 43: Rest of Europe 15-Year Perspective for Sarcoma Drugs
by Treatment Type - Percentage Breakdown of Value Sales for
Targeted Therapy and Chemotherapy for the Years 2012, 2021 &
2027
ASIA-PACIFIC
Sarcoma Drugs Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Asia-Pacific for 2022 (E)
Table 44: Asia-Pacific Recent Past, Current & Future Analysis
for Sarcoma Drugs by Treatment Type - Targeted Therapy and
Chemotherapy - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 45: Asia-Pacific Historic Review for Sarcoma Drugs by
Treatment Type - Targeted Therapy and Chemotherapy Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 46: Asia-Pacific 15-Year Perspective for Sarcoma Drugs by
Treatment Type - Percentage Breakdown of Value Sales for
Targeted Therapy and Chemotherapy for the Years 2012, 2021 &
2027
REST OF WORLD
Table 47: Rest of World Recent Past, Current & Future Analysis
for Sarcoma Drugs by Treatment Type - Targeted Therapy and
Chemotherapy - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 48: Rest of World Historic Review for Sarcoma Drugs by
Treatment Type - Targeted Therapy and Chemotherapy Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 49: Rest of World 15-Year Perspective for Sarcoma Drugs
by Treatment Type - Percentage Breakdown of Value Sales for
Targeted Therapy and Chemotherapy for the Years 2012, 2021 &
2027
IV. COMPETITION
Read the full report: https://www.reportlinker.com/p06032828/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________